

19. (New) An expression vector according to claim 3, wherein the vector is a viral vector selected from the group consisting of an adenovirus vector, adeno-associated virus vector, semliki forest virus vector, sindbis virus vector, pox virus vector, vaccinia virus vector, avian poxvirus vector, avipox virus vector, fowlpox virus vector, canarypox virus vector, alphavirus vector, fowlpox virus vector or lentivirus vector.

20. (New) An isolated polynucleotide according to claim 1, wherein the immunogenic portion is selected from the group consisting of amino acid residues 106-553, 136-547 or 1-472 of the polypeptide encoded by SEQ ID NO: 110.

21. (New) An isolated polynucleotide according to claim 1, wherein the immunogenic portion is selected from the group consisting of amino acid residues 351-472, 351-547, 376-384, 370-379, 411-486, 453-472 or 463-472 of the polypeptide encoded by SEQ ID NO: 110.

AG  
Conc  
22. (New) An isolated polynucleotide according to claim 1, wherein the immunogenic portion is selected from the group consisting of amino acid residues 1-325, 58-76, 39-57 or 1-19 of the polypeptide encoded by SEQ ID NO: 110.

23. (New) An isolated polynucleotide according to claim 1, wherein the immunogenic portion is selected from the group consisting of amino acid residues 439-459 of the polypeptide encoded by SEQ ID NO: 110.

24. (New) An isolated polynucleotide according to claim 1, wherein the immunogenic portion is selected from the group consisting of amino acid residues 306-322 or 296-322 of the polypeptide encoded by SEQ ID NO: 110.

25. (New) An isolated polynucleotide according to claim 1, wherein the immunogenic portion is selected from the group consisting of amino acid residues 181-198 or 296-322 of the polypeptide encoded by SEQ ID NO: 110.

26. (New) An isolated polynucleotide according to claim 1, wherein the immunogenic portion is selected from the group consisting of amino acid residues 543-553 of the polypeptide encoded by SEQ ID NO: 110.

27. (New) A recombinant vector comprising a polynucleotide encoding at least an immunogenic portion of the polypeptide encoded by SEQ ID NO: 110.

28. (New) The vector of claim 27, wherein the vector is a viral vector.

29. (New) The vector of claim 27, wherein the vector is a viral vector selected from the group consisting of an adenovirus vector, adeno-associated virus vector, semliki forest virus vector, sindbis virus vector, pox virus vector, vaccinia virus vector, avian poxvirus vector, avipox virus vector, fowlpox virus vector, canarypox virus vector, alphavirus vector, fowlpox virus vector or lentivirus vector.

AB  
Cont  
30. (New) The vector of claim 27, wherein the immunogenic portion is selected from the group consisting of amino acid residues 106-553, 136-547 or 1-472 of the polypeptide encoded by SEQ ID NO: 110.

31. (New) The vector of claim 27, wherein the immunogenic portion is selected from the group consisting of amino acid residues 351-472, 351-547, 376-384, 370-379, 411-486, 453-472 or 463-472 of the polypeptide encoded by SEQ ID NO: 110.

32. (New) The vector of claim 27, wherein the immunogenic portion is selected from the group consisting of amino acid residues 1-325, 58-76, 39-57 or 1-19 of the polypeptide encoded by SEQ ID NO: 110.

33. (New) The vector of claim 27, wherein the immunogenic portion is selected from the group consisting of amino acid residues 439-459 of the polypeptide encoded by SEQ ID NO: 110.